Published in Antimicrob Agents Chemother on September 01, 2003
Aspergillus infections in transplant recipients. Clin Microbiol Rev (2005) 2.82
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother (2008) 2.70
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol (2004) 2.60
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother (2006) 2.31
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res (2010) 1.77
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother (2006) 1.75
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother (2009) 1.69
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother (2013) 1.63
Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother (2012) 1.57
Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother (2004) 1.46
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother (2008) 1.40
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.39
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother (2008) 1.35
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother (2009) 1.34
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother (2004) 1.33
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother (2007) 1.29
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother (2006) 1.22
Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother (2010) 1.15
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem (2009) 1.10
Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother (2010) 1.07
Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother (2014) 1.05
Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob Agents Chemother (2011) 1.04
Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2012) 1.02
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob Agents Chemother (2009) 1.00
Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother (2012) 0.98
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist (2013) 0.95
Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol (2010) 0.94
Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrob Agents Chemother (2015) 0.94
Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis (2011) 0.90
Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature. Eur J Med Res (2011) 0.90
Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother (2010) 0.89
Skin concentrations and pharmacokinetics of posaconazole after oral administration. Antimicrob Agents Chemother (2010) 0.88
Advances in synthetic approach to and antifungal activity of triazoles. Beilstein J Org Chem (2011) 0.87
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections. Clin Pharmacol (2015) 0.86
Candida infections and their prevention. ISRN Prev Med (2012) 0.86
Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections. Can J Infect Dis Med Microbiol (2008) 0.85
Role of posaconazole in the management of oropharyngeal and esophageal candidiasis. Ther Clin Risk Manag (2007) 0.85
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol (2015) 0.85
Pharmacokinetics of antifungal agents in children. Early Hum Dev (2011) 0.85
Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob Agents Chemother (2005) 0.85
Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. Drug Des Devel Ther (2010) 0.82
Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels. Antimicrob Agents Chemother (2017) 0.79
Pediatric antifungal agents. Curr Opin Infect Dis (2009) 0.79
Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab (2013) 0.79
Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole. Infect Drug Resist (2015) 0.78
Hot melt extruded amorphous solid dispersion of posaconazole with improved bioavailability: investigating drug-polymer miscibility with advanced characterisation. Biomed Res Int (2014) 0.78
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. Antimicrob Agents Chemother (2013) 0.78
Posaconazole in the management of refractory invasive fungal infections. Ther Clin Risk Manag (2008) 0.78
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs (2014) 0.77
Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol (2015) 0.77
Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol (2011) 0.77
Visual Hallucinations Associated with High Posaconazole Concentrations in Serum. Antimicrob Agents Chemother (2015) 0.77
Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrob Agents Chemother (2012) 0.77
The use of antifungal therapy in neonatal intensive care. Clin Perinatol (2012) 0.76
Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2014) 0.76
Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels. Antimicrob Agents Chemother (2016) 0.75
Role of posaconazole in the treatment of oropharyngeal candidiasis. Infect Drug Resist (2010) 0.75
Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review. J Clin Pharm Ther (2016) 0.75
Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist (2016) 0.75
Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma. Mol Cancer Ther (2016) 0.75
Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats. Drugs R D (2017) 0.75
Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case Report. Am J Case Rep (2016) 0.75
Posaconazole Pharmacokinetics in Healthy Cats after Oral and Intravenous Administration. J Vet Intern Med (2016) 0.75
Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase. Pharmaceuticals (Basel) (2010) 0.75
Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Leuk Res Treatment (2017) 0.75
Posaconazole: An Update of Its Clinical Use. Pharmacy (Basel) (2015) 0.75
Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol (2017) 0.75
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol (1998) 7.01
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother (2002) 3.74
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother (2002) 3.40
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother (1996) 3.20
In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother (2002) 2.89
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 2.84
Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis (1999) 2.61
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother (2002) 2.36
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother (2000) 2.33
Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis (1999) 2.28
In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother (2002) 2.15
In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother (2001) 2.03
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother (2000) 1.98
Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (2000) 1.64
In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi. Antimicrob Agents Chemother (2001) 1.42
In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother (2002) 1.42
Novel triazole antifungal agents. Expert Opin Investig Drugs (2000) 1.34
Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy (1998) 1.26
Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs (2002) 1.25
Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother (2001) 1.22
Pharmacology of itraconazole. Drugs (2001) 1.14
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy (2001) 1.13
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol (2006) 3.31
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol (2004) 2.60
Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet (2005) 1.96
Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord (2007) 1.44
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology (2005) 1.40
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother (2004) 1.33
Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol (2002) 1.13
Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J Clin Pharmacol (2008) 1.09
Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. Curr Drug Metab (2009) 1.09
Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma. J Chromatogr A (2003) 1.03
Investigation of Escherichia coli Harboring the mcr-1 Resistance Gene - Connecticut, 2016. MMWR Morb Mortal Wkly Rep (2016) 0.95
Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther (2002) 0.94
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet (2002) 0.87
Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.81
Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of chloroquine in dog plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.79
Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection. Clin Gastroenterol Hepatol (2005) 0.76
Genotypic and phenotypic analyses of hepatitis C virus from patients treated with JTK-853 in a three-day monotherapy. Antimicrob Agents Chemother (2012) 0.75
Neurofacilitation of Developmental Reaction (NFDR) approach: a practice framework for integration / modification of early motor behavior (Primitive Reflexes) in Cerebral Palsy. Indian J Pediatr (2011) 0.75
Notes from the Field: Outbreak of Escherichia coli O157 Infections Associated with Goat Dairy Farm Visits - Connecticut, 2016. MMWR Morb Mortal Wkly Rep (2016) 0.75